Several experimental data are available regarding the efficacy of the combination of interstitial @entity221 and conformal radiation therapy. We planned a phase II trial as a member of the special @entity221 research group of the Deutsche Forschungsgemeinschaft (German Research Society) to determine the efficacy of thermoradiotherapy using interstitial @entity1953 - @entity11720 thermoseeds in the treatment of @entity1 with @entity263 . Forty-one @entity1 with @entity263 were enrolled in the study between July 1997 and April 2000. The interstitial @entity221 induced in a magnetic field was applied in six sessions once a week. Conformal three-dimensional radiation therapy was given simultaneously in daily fractions of 1.8 Gy with a total dose of 68.4 Gy. We measured intraprostatic temperatures between 42 degrees and 46 degrees C. No major side effects were observed during the @entity221 session. The median level of @entity1486 (PSA) decreased from 11.25 ng/ml to 0.88 ng/ml 3 months after treatment and to 0.38 ng/ml 12 months after treatment with a median follow-up of 10 months. The mean prostate volume decreased from 32.6 ml to 26 ml after 3 months of treatment and to 18.5 ml after 12 months. Interstitial @entity221 is a feasible, well-tolerated procedure in @entity263 therapy. A significant PSA decrease was observed. Longer follow-up is necessary to determine the efficacy.

[Thermoradiotherapy with interstitial thermoseeds in treatment of local XXXX . Initial results of a phase II study].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer'] @entity11720 :: ('MESH:D010165', 'Chemical') :: ['palladium'] @entity1953 :: ('MESH:D003035', 'Chemical') :: ['cobalt'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['prostatic carcinoma']
